CalliSpheres drug-loaded microspheres embolization for treating unresectable primary hepatic carcinoma
10.13929/j.issn.1672-8475.2020.07.002
- VernacularTitle: 以载药微球CalliSpheres栓塞治疗不可切除原发性肝癌
- Author:
Weinan LU
1
Author Information
1. Department of the First Intervention, Shengjing Hospital of China Medical University
- Publication Type:Journal Article
- Keywords:
Carcinoma, hepatocellular;
Chemoembolization, therapeutic;
Efficacy;
Safety
- From:
Chinese Journal of Interventional Imaging and Therapy
2020;17(7):389-392
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the short-term efficacy and safety of TACE with CalliSpheres in treatment of unresectable primary hepatic carcinoma (PHC). Methods: Totally of 22 patients with unresectable PHC were treated with CalliSpheres (drug-loaded microspheres) embolization. The therapeutic effect and adverse reactions were then observed. Results: All patients were successfully treated with CalliSpheres embolization. Three days after embolization, the levels of alanine transaminase (ALT), aspartate transaminase (AST) and total bilirubin (TBIL) were higher than those before embolization, while albumin (ALB) was lower than that before embolization (all P<0.05). One month after treatment, there was no significant difference of ALT, AST, TBIL nor ALB compared with those before embolization (all P>0.05). ALT, AST, TBIL 1 month after treatment were lower but ALB was higher than 3 days after treatment (all P<0.05). The objective response rates 1, 3 and 6 months after embolization were 86.36% (19/22), 68.18% (15/22) and 50.00% (11/22), and the disease control rates were 86.36%(19/22), 81.82%(18/22) and 68.18%(15/22), respectively. The postoperative adverse reactions were mainly fever and abdominal pain, and all eased after symptomatic treatment. No serious adverse reaction occurred. Conclusion: TACE with CalliSpheres has good short-term efficacy and safety for treating unresectable PHC.
